Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 1.00 |
| ▸ | KIT | P10721 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 5/20 | 1.00 |
| ▸ | CSF1R | P07333 | 4/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 0.86 |
| ▸ | GAK | O14976 | 1/20 | 0.86 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.86 |
| ▸ | STK10 | O94804 | 1/20 | 0.86 |
| ▸ | EGFR | P00533 | 1/20 | 0.86 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.86 |
| ▸ | LCK | P06239 | 1/20 | 0.86 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.86 |
| ▸ | SRC | P12931 | 1/20 | 0.86 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.86 |
| ▸ | FLT1 | P17948 | 1/20 | 0.86 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.86 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.86 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.86 |
| ▸ | AXL | P30530 | 1/20 | 0.86 |
| ▸ | FLT4 | P35916 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29460355 | 1.00 | PDGFRB (1.00) | PDGFRBKITFLT3CSF1RPLK4 | |
| SCHEMBL13330466 | 0.93 | PDGFRB (1.00) | PDGFRBKITFLT3CSF1RPLK4 | |
| SCHEMBL13524739 | 0.93 | PDGFRB (0.90) | PDGFRBKITFLT3CSF1RPLK4 | |
| Tandutinib SCHEMBL29393910 | 0.93 | PDGFRB (1.00) | PDGFRBKITFLT3CSF1RPLK4 | |
| Tandutinib SCHEMBL927974 | 0.93 | PDGFRB (1.00) | PDGFRBKITFLT3CSF1RPLK4 | |
| SCHEMBL13529590 | 0.92 | PDGFRB (0.89) | PDGFRBKITFLT3CSF1RPLK4 | |
| Tandutinib SCHEMBL2478362 | 0.92 | PDGFRB (0.98) | PDGFRBKITFLT3CSF1RPLK4 | |
| SCHEMBL13330482 | 0.91 | PDGFRB (0.88) | PDGFRBKITFLT3CSF1RPLK4 | |
| SCHEMBL14138789 | 0.91 | PDGFRB (0.84) | PDGFRBKITFLT3CSF1RPLK4 | |
| SCHEMBL13330509 | 0.91 | PDGFRB (1.00) | PDGFRBKITFLT3CSF1RPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8536184-B2 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| CN-103145629-A | Synthetic process of tandutinib for treating solid tumors | ZHU ZHICHENG | 2013-06-12 | — | — | CN | disclosed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-RE43098-E1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1330444-B1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND PROCESS FOR MAKING THEM | MILLENNIUM PHARM INC (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7709640-B2 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7560461-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560461-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1964839-A2 | Quinazoline derivatives as kinase inhibitors | Millennium Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1315715-B1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20060167011-A1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | US | disclosed |
| US-6951937-B2 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1330444-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND PROCESS FOR MAKING NITROGENOUS HETEROCYCLIC COMPOUNDS AND INTERMEDIATES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036587-A2 | PROCESS FOR THE PRODUCTION OF 4-QUINAZOLINYLPIPERAZIN-1-CARBOXYLIC ACID PHENYLAMIDES | COR THERAPEUTICS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDGFRB 10/4885KIT 495/4885FLT3 217/4885 |
| US-20060167011-A1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | NME1, NME2, TNNI3K | PDGFRB 1396/4885KIT 927/4885FLT3 151/4885 |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDGFRB 10/4885KIT 495/4885FLT3 217/4885 |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDGFRB 10/4885KIT 495/4885FLT3 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.